HomepageCGEN • NASDAQ
add
Compugen Ltd
$ 1,76
Na sluitingstijd:(1,14%)-0,020
$ 1,74
Gesloten: 3 jul, 16:38:24 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 1,74
Dag-range
$ 1,73 - $ 1,80
Jaar-range
$ 1,13 - $ 2,66
Beurswaarde
157,59 mln. USD
Gem. volume
235,56K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 2,28 mln. | -10,75% |
Bedrijfskosten | 8,28 mln. | -7,49% |
Netto inkomsten | -7,18 mln. | 1,18% |
Netto winstmarge | -314,40 | -10,71% |
Winst per aandeel | -0,08 | 0,00% |
EBITDA | -8,27 mln. | 1,19% |
Effectief belastingtarief | -0,43% | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 103,74 mln. | 2,40% |
Totale activa | 115,44 mln. | 1,53% |
Totale passiva | 58,34 mln. | 7,98% |
Totaal aandelenvermogen | 57,11 mln. | — |
Uitstaande aandelen | 92,31 mln. | — |
Koers-boekwaardeverhouding | 2,81 | — |
Rendement op activa | -18,22% | — |
Rendement op kapitaal | -35,66% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -7,18 mln. | 1,18% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Opgericht
10 feb 1993
Website
Werknemers
74
